Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02601950 · ClinicalTrials.gov registry record · Phase 2
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
A Phase 2 study, sponsored by Epizyme.
- Completed
- Registry status
- Phase 2
- Development phase
- 267
- Enrollment target
NCT02601950 is a Phase 2 study that has completed, run by Epizyme. The registered enrollment target is 267 participants.
The verdict
NCT02601950, a Phase 2 study, has completed, sponsored by Epizyme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 267 participants
- Enrollment target
Study Summary
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body. Part 1 of this trial will study the safety and the level that adverse effects of the study drug tazemetostat in combination with doxorubicin (current front line treatment) can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for the next part of the study. Part 2 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug plus doxorubicin versus doxorubicin plus placebo (dummy treatment).
Interventions
- DRUG Tazemetostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 267 participants |
| Start Date | 2015-12-22 |
| Est. Completion | 2024-02-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02601950
The ClinicalTrials.gov registry entry for NCT02601950 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 267 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tazemetostat is the first listed.
NCT02601950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02601950 about?
NCT02601950 is a clinical study titled "A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma". This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments. Soft tissue cancers are rare and can occur almost anywhere in the body...
What is the current status of trial NCT02601950?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 267 participants. The study started on 2015-12-22. Estimated completion is 2024-02-26.
What interventions are being tested in trial NCT02601950?
The interventions under investigation include: Tazemetostat (DRUG).
Who is sponsoring clinical trial NCT02601950?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.